ГАТТИ МАКАРТУР Сильвия (CH),ЗАКСЕ Михель (CH),ВИХМАНН Юрген (DE),ВОЛЬТЕРИНГ Томас (DE)
申请号：
RU2015116749
公开号：
RU2015116749A
申请日:
2013.10.21
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. The use of the negative allosteric modulator mGlu2 / 3 for the treatment, prevention and / or delay of progression of the states of the central nervous system caused by defects in neurological development, which lead to excessive activation of the mGlu2 / 3 receptor in the central nervous system, and / or which can be corrected by negative allosteric mGlu2 / 3.2 receptor activation modulation. The use according to claim 1, preventing and / or delaying the progression of central nervous system conditions caused by defects in neurological development, which lead to excessive inhibition of mGlu2 / 3 in the cortex and hippocampus. 3. The use according to claim 1, wherein said state of the central nervous system is an autism spectrum disorder. The use of claim 1, wherein said state of the central nervous system is autism. The use of claim 1, wherein the mGlu2 / 3 negative allosteric modulator is selected from a compound of formula (I) and formula (II), wherein each E and J is N, G is C, and one of L or M is N, and the other is CH； or L and G are N, E is C, and J and M are CH； or J, G and L are N, E is C, and M is CH； or E and L are N, J and M are CH, and G is C； A is selected from the group consisting of phenyl, pyridin-2-yl, pyrid in-3-yl, pyridin-4-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-2-yl, pyridazin-3-yl, thiazol-2-yl, thiazol-5-yl and thiophen- 2-yl, which may be substituted with one to four R； B is selected from the group consisting of imidazolyl, [1,2,4] oxadiazolyl, pyrrolyl, 1H-pyrazolyl, pyridinyl, [1,2,4] triazolyl, pyrimidinyl and1. Применение отрицательного аллостерического модулятора mGlu2/3 для лечения, предупреждения и/или задержки прогрессирования состояний центральной нервной системы, вызванных дефектами неврологического развития, которые приводят к избыточной активации рецептора mGlu2/3 в центральной нервной системе, и/или которые могут корректироваться отрицательной аллостерической модуляцией активации рецептора mGlu2/3.2. Применение по п.
